Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of adagrasib versus docetaxel in previously treated KRAS G12C-mutated non-small cell lung cancer
CTR20221262Phase 3Active
- Sponsor
- Mirati Therapeutics
- Start
- Jul 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of adagrasib in non-small cell lung cancer (NSCLC), sponsored by Mirati Therapeutics. Started Jul 2022; status: active.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20221262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221262.